Evidence map›Paper›PMID 22229731›Full record

ArticleScandinavian journal of immunology2012

A novel mutation W388X underlying properdin deficiency in a Finnish family.

M Helminen, S Seitsonen, H Jarva, S Meri, I E Järvelä

Open access · bronzeAbstract readCase Reports
In one paragraph

Article in Scandinavian journal of immunology, 2012. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 6 papers.

0numbers the graph read from it
0cells of the map it votes in
6citing papers in PubMed
0.1field-weighted citation impact, top 50% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

6 citing papers in PubMed, 11 citations in OpenAlex.

  1. Review
  2. Review
  3. Article
  4. Article
  5. Article
  6. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors at 2 institutions in 1 country.

M HelminenDepartment of Pediatrics, Tampere University Hospital, University of Tampere, Tampere, Finland. merja.helminen@pshp.fi
S Seitsonen
H Jarva
S Meri
I E Järvelä
University of Helsinki · FITampere University Hospital · FI

Funding

Development of Complement Modulating Therapeutics for AMDR24EY017404 · NEI · UNIVERSITY OF UTAH · PI HAGEMAN, GREGORY S · 2006 to 2010
$14.8M
AGE-RELATED MACULOPATHY: CELLULAR AND MOLECULAR ANALYSESR01EY011515 · NEI · UNIVERSITY OF IOWA · PI HAGEMAN, GREGORY S · 1996 to 2005
$3.2M
NEI NIH HHS EY11515NEI NIH HHS R01 EY011515NEI NIH HHS R24 EY017404NEI NIH HHS R24EY017404
6 · The paper itself

Abstract

Properdin deficiency is a rare immunological disorder inherited as an X-chromosomal recessive trait. Properdin deficiency poses a significant risk for severe meningococcal infections. About 20 mutations have been reported to underlie properdin deficiency. Here we report a large Finnish family with a novel mutation in the properdin gene (CFP). Based on the total absence of properdin activity in a 14-year-old male patient with an infection resembling meningococcal bacteraemia, the coding region and splice sites of the gene were sequenced. The mutation is located in exon 9 and changes guanine to adenine at nucleotide 1164 (c.1164G>A) that causes tryptophan to change to a premature stop codon (W388X). The mother of the patient was shown to be a carrier of the mutation. In total, the mutation was identified in six females and three young males in the family. The mutation must be inherited from the grandfather who had died of an unknown infectious disease. This is the first mutation of the properdin gene identified in Finland.

Indexed as

MutationAdolescentBacteremiaExonsFemaleFinlandHumansMaleMeningococcal InfectionsPedigreeProperdinProperdin

Identifiers

PMID22229731
PMCPMC3306489
OpenAlexW1586779094

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.